ArticleMediators of inflammation2026
Elevated Inflammatory Burden Index Is Association With Increased Sarcopenia: A Population-Based Study.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elevated Inflammatory Burden Index Is Association With Increased Sarcopenia: A Population-Based Study.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe inflammatory burden index (IBI) is a comprehensive indicator of the inflammatory state of the body and is associated with a variety of chronic diseases. Sarcopenia is a disease characterized by a reduction in skeletal muscle mass, but the association between IBI and sarcopenia is currently unclear.
methodsThis study was based on data from the National Health and Nutrition Examination Survey (NHANES) 2015-2018 and included 4523 participants aged 20 years and older. IBI was calculated by the product of C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR). Sarcopenia was defined by the extremity skeletal muscle mass index (ASM/body mass index [BMI]). The association between IBI and sarcopenia was analyzed using multivariate logistic regression models with nonlinear and subgroup analyses.
resultsThe mean age of the participants was 39.9 years, and 52.5% were female. Higher IBI scores were associated with a higher risk of chronic disease. IBI was positively associated with sarcopenia, with the highest IBI group having a 1.94 times greater risk of sarcopenia than the lowest group (95% CI: 1.34-2.81). The natural log transformation of IBI resulted in a 42% increase in risk of sarcopenia for each unit increase (95% CI: 1.08-1.87). Nonlinear analyses showed an inflection point in the association between IBI and sarcopenia at 2.38, with a significant increase in risk before the inflection point and no longer significant after the inflection point. Subgroup analyses showed that this association was consistent across sex, age, diabetes, cardiovascular disease (CVD), and chronic kidney disease (CKD).
conclusionThere is a positive association between IBI and sarcopenia with nonlinear characteristics. High IBI levels may increase the risk of sarcopenia, suggesting that inflammation may play an important role in sarcopenia, providing a potential target for future interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.